Posted on 4/22/20

Mirati Therapeutics, Inc.: Cracking KRAS Is Harder Than It Looks

SummaryMirati’s KRAS inhibitor MRTX-849 will likely fail as a second line monotherapy in KRAS-mutant NSCLC.Consensus is emerging that Amgen’s AMG-510, with an identical mechanism of action, . . .